المؤلفون: M. I. Strokova, T. B. Morgunova, V. V. Fadeev, М. И. Строкова, Т. Б. Моргунова, В. В. Фадеев

المصدر: Meditsinskiy sovet = Medical Council; № 23 (2023); 202-207 ; Медицинский Совет; № 23 (2023); 202-207 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: пандемия, de Quervain thyroiditis, thyrotoxicosis, SARS-CoV-2, pandemic, тиреоидит де Кервена, тиреотоксикоз

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/8019/7111Test; Poorolajal J. The global pandemics are getting more frequent and severe. J Res Health Sci. 2021;21(1):e00502. https://doi.org/10.34172/jrhs.2021.40Test.; Stasiak M, Lewiński A. New aspects in the pathogenesis and management of subacute thyroiditis. Rev Endocr Metab Disord. 2021;22(4):1027–1039. https://doi.org/10.1007/s11154-021-09648-yTest.; Gorini F, Vassalle C. A Literature review on SARS-CoV-2 and other viruses in thyroid disorders: environmental triggers or no-guilty bystanders? Int J Environ Res Public Health. 2023;20(3):2389. https://doi.org/10.3390/ijerph20032389Test.; Desailloud R, Hober D. Viruses and thyroiditis: an update. Virol J. 2009;6:5. https://doi.org/10.1186/1743-422X-6-5Test.; Brancatella A, Ricci D, Viola N, Sgrò D, Santini F, Latrofa F. Subacute thyroiditis after Sars-COV-2 infection. J Clin Endocrinol Metab. 2020;105(7):dgaa276. https://doi.org/10.1210/clinem/dgaa276Test.; Tabassom A, Chippa V, Edens MA. De Quervain Thyroiditis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK526066Test.; Mundy-Baird G, Kyriacou A, Syed AA. De Quervain subacute thyroiditis. CMAJ. 2021;193(26):E1007. https://doi.org/10.1503/cmaj.202787Test.; Martinez Quintero B, Yazbeck C, Sweeney LB. Thyroiditis: Evaluation and Treatment. Am Fam Physician. 2021;104(6):609–617. Available at: https://pubmed.ncbi.nlm.nih.gov/34913664Test.; Fatourechi V, Aniszewski JP, Fatourechi GZ, Atkinson EJ, Jacobsen SJ. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab. 2023;88(5):2100–2105. https://doi.org/10.1210/jc.2002-021799Test.; Alfadda AA, Sallam RM, Elawad GE, Aldhukair H, Alyahya MM. Subacute thyroiditis: clinical presentation and long term outcome. Int J Endocrinol. 2014;794943. https://doi.org/10.1155/2014/794943Test.; Görges J, Ulrich J, Keck C, Müller-Wieland D, Diederich S, Janssen OE. Longterm outcome of subacute thyroiditis. Exp Clin Endocrinol Diabetes. 2020;128(11):703–708. https://doi.org/10.1055/a-0998-8035Test.; Hepşen S, Saat H, Akhanli P, Cakal E. The management of repetitive subacute thyroiditis in a male patient having HLA-B35:01 and B41:02 alleles. Acta Endocrinol (Buchar). 2022;18(4):512–515. https://doi.org/10.4183/aeb.2022.512Test.; Yasuda S, Suzuki S, Yanagisawa S, Morita H, Haisa A, Satomura A et al. HLA typing of patients who developed subacute thyroiditis and Graves’ disease after SARS-CoV-2 vaccination: a case report. BMC Endocr Disord. 2023;23(1):54. https://doi.org/10.1186/s12902-023-01287-5Test.; Stasiak M, Tymoniuk B, Stasiak B, Lewiński A. The risk of recurrence of subacute thyroiditis is HLA-dependent. Int J Mol Sci. 2019;20(5):1089. https://doi.org/10.3390/ijms20051089Test.; Ray I, D’Souza B, Sarker P, Agarwal P. Management of subacute thyroiditis – a systematic review of current treatment protocols. Int J Gen Med. 2022;15:6425–6439. https://doi.org/10.2147/IJGM.S366784Test.; Muller I, Cannavaro D, Dazzi D, Covelli D, Mantovani G, Muscatello A et al. SARS-CoV-2-related atypical thyroiditis. Lancet Diabetes Endocrinol. 2020;8(9):739–741. https://doi.org/10.1016/S2213-8587Test(20)30266-7.; Mattar SAM, Koh SJQ, Rama Chandran S, Cherng BPZ. Subacute thyroiditis associated with COVID-19. BMJ Case Rep. 2020;13(8):e237336. https://doi.org/10.1136/bcr-2020-237336Test.; Rotondi M, Coperchini F, Ricci G, Denegri M, Croce L, Ngnitejeu ST et al. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis. J Endocrinol Invest. 2021;44(5):1085–1090. https://doi.org/10.1007/s40618-020-01436-wTest.; Lazarus JH. Silent thyroiditis and subacute thyroiditis. In: Braverman LE, Utiger RD (eds.). The Thyroid: A Fundamental and Clinical Text. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 1996. 577 р.; Тимофеева ЛА, Александров ЮК, Алешина ТН, Юсова МА. Подострый тиреоидит, ассоциированный с COVID-19. Российский электронный журнал лучевой диагностики. 2021;11(3):15–24. https://doi.org/10.21569/2222-7415-2021-11-3-15-24Test.; Chen Y, Zhu S, Chen H, Yao L, Zhou J, Xu Y et al. Diagnostic value of color doppler ultrasonography in subacute thyroiditis. Scanning. 2022:7456622. https://doi.org/10.1155/2022/7456622Test.; Cappelli C, Pirola I, Gandossi E, Formenti AM, Agosti B, Castellano M. Ultrasound findings of subacute thyroiditis: a single institution retrospective review. Acta Radiol. 2014;55(4):429–433. https://doi.org/10.1177/0284185113498721Test.; Lee YJ, Kim DW. Sonographic characteristics and interval changes of subacute thyroiditis. J Ultrasound Med. 2016;35(8):1653–1659. https://doi.org/10.7863/ultra.15.09049Test.; Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;348(26):2646–2655. https://doi.org/10.1056/NEJMra021194Test.; Aemaz Ur Rehman M, Farooq H, Ali MM, Ebaad Ur Rehman M, Dar QA, Hussain A. The association of subacute thyroiditis with COVID-19: a systematic review. SN Compr Clin Med. 2021;3(7):1515–1527. https://doi.org/10.1007/s42399-021-00912-5Test.; Christensen J, O’Callaghan K, Sinclair H, Hawke K, Love A, Hajkowicz K, Stewart AG. Risk factors, treatment and outcomes of subacute thyroiditis secondary to COVID-19: a systematic review. Int Med J. 2022;52(4):522–529. https://doi.org/10.1111/imj.15432Test.; Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino Ch, Hasell J et al. Coronavirus Pandemic (COVID-19). 2020.; Wijenayake UN, Ratnayake GM, Abeyratne D, Bulugahapitiya US. A case report of subacute thyroiditis after inactivated SARS-CoV-2 vaccine. SAGE Open Med Case Rep. 2022;10:2050313X221140243. https://doi.org/10.1177/2050313X221140243Test.; Plaza-Enriquez L, Khatiwada P, Sanchez-Valenzuela M, Sikha A. A case report of subacute thyroiditis following mRNA COVID-19 vaccine. Case Rep Endocrinol. 2021:8952048. https://doi.org/10.1155/2021/8952048Test.; Adelmeyer J, Goebel JN, Kauka A, Kann PH. Two case reports of subacute thyroiditis after receiving vaccine for COVID-19. Case Rep Endocrinol. 2022:2022:3180004. https://doi.org/10.1155/2022/3180004Test.; Frangos S, Haralambous H, Michael K, Economides PA. Subacute thyroiditis after the third dose of the COVID-19 mRNA vaccine. Case report. Hell J Nucl Med. 2022:25(2):210–212. https://doi.org/10.1967/s002449912481Test.; Cohen Tervaert JW, Martinez-Lavin M, Jara LJ, Halpert G, Watad A, Amital H, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) in 2023. Autoimmun Rev. 2023;22(5):103287. https://doi.org/10.1016/j.autrev.2023.103287Test.; Pulendran B, Arunachalam PS, O’Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021;20(6):454–475. https://doi.org/10.1038/s41573-021-00163-yTest.; Facciolà A, Visalli G, Laganà A, Di Pietro A. An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives. Vaccines (Basel). 2022;10(5):819. https://doi.org/10.3390/vaccines10050819Test.; Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2020;217:108480. https://doi.org/10.1016/j.clim.2020.108480Test.; Pipitone G, Rindi LV, Petrosillo N, Foti NAM, Caci G, Iaria C et al. Vaccine-induced subacute thyroiditis (De Quervain’s) after mRNA vaccine against SARS-CoV-2: a case report and systematic review. Infect Dis Rep. 2022;14(1):142–154. https://doi.org/10.3390/idr14010018Test.; Oğuz SH, Şendur SN, İremli BG, Gürlek A, Erbas T, Ünlütürk U. SARS-CoV-2 vaccine-induced thyroiditis: safety of revaccinations and clinical follow-up. J Clin Endocrinol Metab. 2022;107(5):e1823–e1834. https://doi.org/10.1210/Clinem/dgac049Test.; Bahçecioğlu AB, Karahan ZC, Aydoğan BI, Kalkan IA, Azap A, Erdoğan MF. Subacute thyroiditis during the COVID-19 pandemic: a prospective study. J Endocrinol Invest. 2022;45(4):865–874. https://doi.org/10.1007/s40618021-01718-xTest.; Sarker R, Roknuzzaman ASM, Nazmunnahar Hossain MJ, Islam MR. Benefits and probable ill effects of WHO’s declaration of end of COVID-19 pandemic: a way back to pandemic-free normal life. Ann Med Surg (Lond). 2023;85(6):3199–3201. https://doi.org/10.1097/MS9.0000000000000848Test.; https://www.med-sovet.pro/jour/article/view/8019Test

الإتاحة: https://doi.org/10.21518/ms2023-473Test
https://doi.org/10.34172/jrhs.2021.40Test
https://doi.org/10.1007/s11154-021-09648-yTest
https://doi.org/10.1186/1743-422X-6-5Test
https://doi.org/10.1210/clinem/dgaa276Test
https://doi.org/10.1503/cmaj.202787Test
https://doi.org/10.1210/jc.2002-021799Test
https://doi.org/10.1155/2014/794943Test
https://doi.org/10.1055/a-0998-8035Test
https://doi.org/10.4183/aeb.2022.512Test

المؤلفون: T. B. Morgunova, I. V. Glinkina, E. D. Pesheva, A. A. Zorina, V. V. Fadeev, Т. Б. Моргунова, И. В. Глинкина, Е. Д. Пешева, А. А. Зорина, В. В. Фадеев

المصدر: Meditsinskiy sovet = Medical Council; № 13 (2023); 122-129 ; Медицинский Совет; № 13 (2023); 122-129 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: терапевтическое применение, glucose lowering drug, metformin, glycemic control, therapeutic use, сахароснижающий препарат, метформин, гликемический контроль

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7720/6855Test; Дедов И.И., Шестакова М.В., Майоров А.Ю. (ред.). Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 11-й выпуск. М.; 2023. 234 с. Режим доступа: https://webmed.irkutsk.ru/doc/pdf/algosd.pdfTest.; Montvida O., Shaw J., Atherton J.J., Stringer F., Paul S.K. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes. Diabetes Care. 2018;41(1):69–78. https://doi.org/10.2337/dc17-1414Test.; Maruthur N.M., Tseng E., Hutfless S., Wilson L.M., Suarez-Cuervo C., Berger Z. et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med. 2016;164(11):740–751. https://doi.org/10.7326/M15-2650Test.; Fang M., Wang D., Coresh J., Selvin E. Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018. N Engl J Med. 2021;384(23):2219–2228. https://doi.org/10.1056/NEJMsa2032271Test.; Hadden D.R. Goat’s rue – French lilac – Italian fitch – Spanish sainfoin: gallega officinalis and metformin: the Edinburgh connection. J R Coll Physicians Edinb. 2005;35(3):258–260. Available at: https://pubmed.ncbi.nlm.nih.gov/16402501Test.; Keeler R.F., Baker D.C., Evans J.O. Individual animal susceptibility and its relationship to induced adaptation or tolerance in sheep to Galega officinalis L. Vet Hum Toxicol. 1988;30(5):420–423. Available at: https://pubmed.ncbi.nlm.nih.gov/3188360Test.; Bailey C.J., Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care. 1989;12(8):553–564. https://doi.org/10.2337/diacare.12.8.553Test.; Mckendry J.B., Kuwayti K., Rado P.P. Clinical experience with DBI (phenformin) in the management of diabetes. Can Med Assoc J. 1959;80(10):773–778. Available at: https://pubmed.ncbi.nlm.nih.gov/13652024Test.; Bailey C.J. Metformin: historical overview. Diabetologia. 2017;60(9):1566–1576. https://doi.org/10.1007/s00125-017-4318-zTest.; IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med. 2006;23(6):579–593. https://doi.org/10.1111/j.1464-5491.2006.01918.xTest.; Смирнова О.М. Место метформина в современном лечении и профилактике сахарного диабета 2 типа. Сахарный диабет. 2010;13(3):83–90. https://doi.org/10.14341/2072-0351-5494Test.; American Diabetes Association. Standards of Medical Care in Diabetes – 2021. Diabetes Care. 2021;44(Suppl. 1):111–124. https://doi.org/10.2337/dc21-S009Test.; Garber A.J., Handelsman Y., Grunberger G., Einhorn D., Abrahamson M.J., Barzilay J.I. et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2020. Endocr Pract. 2020;26(1):107–139. https://doi.org/10.4158/CS-2019-0472Test.; Cosentino F., Grant P.J., Aboyans V., Bailey C.J., Ceriello A., Delgado V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. https://doi.org/10.1093/eurheartj/ehz486Test.; Blonde L., Umpierrez G.E., Reddy S.S., McGill J.B., Berga S.L., Bush M. et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan – 2022 Update. Endocr Pract. 2022;28(10):923–1049. https://doi.org/10.1016/j.eprac.2022.08.002Test.; Sanchez-Rangel E., Inzucchi S.E. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586–1593. https://doi.org/10.1007/s00125-017-4336-xTest.; Hostalek U., Gwilt M., Hildemann S. Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. Drugs. 2015;75(10):1071–1094. https://doi.org/10.1007/s40265-015-0416-8Test.; Matthews D.R., Paldánius P.M., Proot P., Chiang Y., Stumvoll M., Del Prato S.; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519–1529. https://doi.org/10.1016/S0140-6736Test(19)32131-2.; Sivitz W.I., Phillips L.S., Wexler D.J., Fortmann S.P., Camp A.W., Tiktin M. et al. Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. Diabetes Care. 2020;43(5):940–947. https://doi.org/10.2337/dc19-1769Test.; Garber A.J., Duncan T.G., Goodman A.M., Mills D.J., Rohlf J.L. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103(6):491–497. https://doi.org/10.1016/s0002-9343Test(97)00254-4.; Mahabaleshwarkar R., DeSantis A. Metformin dosage patterns in type 2 diabetes patients in a real-world setting in the United States. Diabetes Res Clin Pract. 2021;172:108531. https://doi.org/10.1016/j.diabres.2020.108531Test.; Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104–112. https://doi.org/10.14341/DM2004116-17Test.; Ali M.K., Bullard K.M., Saydah S., Imperatore G., Gregg E.W. Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988–2014. Lancet Diabetes Endocrinol. 2018;6(5):392–403. https://doi.org/10.1016/S2213-8587Test(18)30027-5.; Vistisen D., Witte D.R., Brunner E.J., Kivimäki M., Tabák A., Jørgensen M.E., Færch K. Risk of Cardiovascular Disease and Death in Individuals With Prediabetes Defined by Different Criteria: The Whitehall II Study. Diabetes Care. 2018;41(4):899–906. https://doi.org/10.2337/dc17-2530Test.; Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012;35(4):731–737. https://doi.org/10.2337/dc11-1299Test.; Diabetes Prevention Program Research Group. Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2019;42(4):601–608. https://doi.org/10.2337/dc18-1970Test.; Walker E.A., Gonzalez J.S., Tripputi M.T., Dagogo-Jack S., Matulik M.J., Montez M.G. et al. Group. Long-term metformin adherence in the Diabetes Prevention Program Outcomes Study. BMJ Open Diabetes Res Care. 2020;8(1):e001537. https://doi.org/10.1136/bmjdrc-2020-001537Test.; Hughes A., Khan T., Kirley K., Moin T., Mainous A., Sachdev N. et al. Metformin Prescription Rates for Patients with Prediabetes. J Am Board Fam Med. 2022;35(4):821–826. https://doi.org/10.3122/jabfm.2022.04.210485Test.; McCreight L.J., Bailey C.J., Pearson E.R. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426–435. https://doi.org/10.1007/s00125015-3844-9Test.; Bonnet F., Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab. 2017;19(4):473–481. https://doi.org/10.1111/dom.12854Test.; Wee A.K.H., Sultana R. Determinants of vitamin B12 deficiency in patients with type-2 diabetes mellitus – A primary-care retrospective cohort study. BMC Prim Care. 2023;24(1):102. https://doi.org/10.1186/s12875-023-02057-xTest.; Rathis T.S., Ranganathan R.S., Solai Raja M., Srivastav P.S.S. Prevalence of Vitamin B12 Deficiency in Type 2 Diabetes Mellitus Patients on Metformin Therapy. Cureus. 2023;15(4):e37466. https://doi.org/10.7759/cureus.37466Test.; Kim J., Ahn C.W., Fang S., Lee H.S., Park J.S. Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes. Medicine (Baltimore). 2019;98(46):e17918. https://doi.org/10.1097/MD.0000000000017918Test.; Aroda V.R., Edelstein S.L., Goldberg R.B., Knowler W.C., Marcovina S.M., Orchard T.J. et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754–1761. https://doi.org/10.1210/jc.2015-3754Test.; Liu L., Simon B., Shi J., Mallhi A.K., Eisen H.J. Impact of diabetes mellitus on risk of cardiovascular disease and all-cause mortality: Evidence on health outcomes and antidiabetic treatment in United States adults. World J Diabetes. 2016;7(18):449–461. https://doi.org/10.4239/wjd.v7.i18.449Test.; Khunti K., Millar-Jones D. Clinical inertia to insulin initiation and intensification in the UK: A focused literature review. Prim Care Diabetes. 2017;11(1):3–12. https://doi.org/10.1016/j.pcd.2016.09.003Test.; Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854865. Available at: https://pubmed.ncbi.nlm.nih.gov/9742977Test.; Hong J., Zhang Y., Lai S., Lv A., Su Q., Dong Y. et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36(5):1304–1311. https://doi.org/10.2337/dc12-0719Test.; Selvin E., Bolen S., Yeh H.C., Wiley C., Wilson L.M., Marinopoulos S.S. et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;168(19):2070–2080. https://doi.org/10.1001/archinte.168.19.2070Test.; Han Y., Xie H., Liu Y., Gao P., Yang X., Shen Z. Effect of metformin on allcause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019;18(1):96. https://doi.org/10.1186/s12933-019-0900-7Test.; Kim Y., Kim H.S., Lee J.W., Kim Y.S., You H.S., Bae Y.J. et al. Metformin use in el der ly population with diabetes reduced the risk of dementia in a dose-dependent manner, based on the Korean NHIS-HEALS cohort. Diabetes Res Clin Pract. 2020;170:108496. https://doi.org/10.1016/j.diabres.2020.108496Test.; Zhang Q.Q., Li W.S., Liu Z., Zhang H.L., Ba Y.G., Zhang R.X. Metformin therapy and cognitive dysfunction in patients with type 2 diabetes: A meta-analysis and systematic review. Medicine (Baltimore). 2020;99(10):e19378. https://doi.org/10.1097/MD.0000000000019378Test.; https://www.med-sovet.pro/jour/article/view/7720Test

الإتاحة: https://doi.org/10.21518/ms2023-211Test
https://doi.org/10.2337/dc17-1414Test
https://doi.org/10.7326/M15-2650Test
https://doi.org/10.1056/NEJMsa2032271Test
https://doi.org/10.2337/diacare.12.8.553Test
https://doi.org/10.1007/s00125-017-4318-zTest
https://doi.org/10.1111/j.1464-5491.2006.01918.xTest
https://doi.org/10.14341/2072-0351-5494Test
https://doi.org/10.2337/dc21-S009Test
https://doi.org/10.4158/CS-2019-0472Test

المؤلفون: A. V. Balashova, I. V. Glinkina, M. G. Pavlova, A. V. Oderiy, V. V. Fadeev, А. B. Балашова, И. В. Глинкина, М. Т. Павлова, А. В. Одерий, В. В. Фадеев

المصدر: Meditsinskiy sovet = Medical Council; № 10 (2022); 22-32 ; Медицинский Совет; № 10 (2022); 22-32 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: когнитивное нарушение, diabetes mellitus type 2, therapeutic education, diabetes self-management education, geriatric syndrome, functional status, cognitive impairment, сахарный диабет 2-го типа, терапевтическое обучение, гериатрический синдром, функциональный статус

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/6904/6234Test; Jain A., Paranjape S. Prevalence of type 2 diabetes mellitus in elderly in a primary care facility: An ideal facility. Indian J Endocrinol Metab. 2013;17(1 Suppl.):S318–S322. https://doi.org/10.4103/2230-8210.119647Test.; Sun Y., Ni W., Yuan X., Chi H., Xu J. Prevalence, treatment, control of type 2 diabetes and the risk factors among elderly people in Shenzhen: results from the urban Chinese population. BMC Public Health. 2020;20(1):998. https://doi.org/10.1186/s12889-020-09045-1Test.; American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(1 Suppl.):S168–S179. https://doi.org/10.2337/dc21-S012Test.; Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А. Сахарный диабет в Российской Федерации: распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета, статус 2017 г. Сахарный диабет. 2018;21(3):144–159. https://doi.org/10.14341/DM9686Test.; LeRoith D., Biessels G.J., Braithwaite S.S., Casanueva F.F., Draznin B., Halter J.B. et al. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1520–1574. https://doi.org/10.1210/jc.2019-00198Test.; Powers M.A., Bardsley J., Cypress M., Duker P., Funnell M.M., Hess Fischl A. et al. Diabetes Self-management Education and Support in Type 2 Diabetes: A Joint Position Statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Diabetes Care. 2015;38(7):1372–1382. https://doi.org/10.2337/dc15-0730Test.; Sherr D., Lipman R.D. The Diabetes Educator and the Diabetes Self-management Education Engagement: The 2015 National Practice Survey. Diabetes Educ. 2015;41(5):616–624. https://doi.org/10.1177/0145721715599268Test.; Светый Л.И., Ворвуль А.О., Маркина Е.В., Ивих К.А., Руссу А.А. Результаты обучения в школе диабета пожилых лиц, страдающих сахарным диабетом II типа. Современные проблемы здравоохранения и медицинской статистики. 2020;(1):82–91. https://doi.org/10.24411/2312-2935-2020-00007Test.; Owens B. Profile: Joslin Diabetes Center, Boston, MA, USA. Lancet. 2015;386(9997):944. https://doi.org/10.1016/S0140-6736Test(15)00116-6.; Майоров А.Ю., Суркова Е.В., Мотовилин О.Г., Мельникова О.Г., Шишкова Ю.А. Обучение больных диабетом: синтез доказательной медицины и психологического подхода. Сахарный диабет. 2011;14(1):46–52. https://doi.org/10.14341/2072-0351-6249Test.; Powers M.A., Bardsley J., Cypress M., Duker P., Funnell M.M., Fischl A.H. et al. Diabetes Self-management Education and Support in Type 2 Diabetes: A Joint Position Statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Clin Diabetes. 2016;34(2):70–80. https://doi.org/10.2337/diaclin.34.2.70Test.; Аметов А.С., Валитов Б., Черникова Н.А. Терапевтическое обучение больных: прошлое, настоящее, будущее. Сахарный диабет. 2012;15(1):71–77. https://doi.org/10.14341/2072-0351-5982Test.; Thongsai S., Youjaiyen M. The long-term impact of education on diabetes for older people: a systematic review. Glob J Health Sci. 2013;5(6):30–39. https://doi.org/10.5539/gjhs.v5n6p30Test.; Bekele B.B., Negash S., Bogale B., Tesfaye M., Getachew D., Weldekidan F., Balcha B. The effectiveness of diabetes self-management education (DSME) on glycemic control among T2DM patients randomized control trial: systematic review and meta-analysis protocol. J Diabetes Metab Disord. 2020;19(2):1631–1637. https://doi.org/10.1007/s40200-020-00584-3Test.; Mikhael E.M., Hassali M.A., Hussain S.A. Effectiveness of Diabetes SelfManagement Educational Programs for Type 2 Diabetes Mellitus Patients In Middle East Countries: A Systematic Review. Diabetes Metab Syndr Obes. 2020;13:117–138. https://doi.org/10.2147/DMSO.S232958Test.; Murray C.M., Shah B.R. Diabetes self-management education improves medication utilization and retinopathy screening in the elderly. Prim Care Diabetes. 2016;10(3):179–185. https://doi.org/10.1016/j.pcd.2015.10.007Test; Kent D., D’Eramo Melkus G., Stuart P.M., McKoy J.M., Urbanski P., Boren S.A. et al. Reducing the risks of diabetes complications through diabetes self-management education and support. Popul Health Manag. 2013;16(2):74–81. https://doi.org/10.1089/pop.2012.0020Test; American Diabetes Association. 5. Facilitating Behavior Change and Wellbeing to Improve Health Outcomes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(1 Suppl.):S53–S72. https://doi.org/10.2337/dc21-S005Test.; Suhl E., Bonsignore P. Diabetes Self-Management Education for Older Adults: General Principles and Practical Application. Diabetes Spectr. 2006;19(4):234–240. https://doi.org/10.2337/diaspect.19.4.234Test.; Braun A.K., Kubiak T., Kuntsche J., Meier-Höfig M., Müller U.A., Feucht I., Zeyfang A. SGS: a structured treatment and teaching programme for older patients with diabetes mellitus – a prospective randomised controlled multi-centre trial. Age Ageing. 2009;38(4):390–396. https://doi.org/10.1093/ageing/afp056Test.; Lee S.J., Song M., Im E.O. Effect of a Health Literacy-Considered Diabetes Self-Management Program for Older Adults in South Korea. Res Gerontol Nurs. 2017;10(5):215–225. https://doi.org/10.3928/19404921-20170831-03Test.; Beverly E.A., Fitzgerald S., Sitnikov L., Ganda O.P., Caballero A.E., Weinger K. Do older adults aged 60–75 years benefit from diabetes behavioral interventions? Diabetes Care. 2013;36(6):1501–1506. https://doi.org/10.2337/dc12-2110Test.; Shah B.R., Hwee J., Cauch-Dudek K., Ng R., Victor J.C. Diabetes self-management education is not associated with a reduction in long-term diabetes complications: an effectiveness study in an elderly population. J Eval Clin Pract. 2015;21(4):656–661. https://doi.org/10.1111/jep.12360Test.; Sperl-Hillen J., Beaton S., Fernandes O., Von Worley A., Vazquez-Benitez G., Parker E. et al. Comparative effectiveness of patient education methods for type 2 diabetes: a randomized controlled trial. Arch Intern Med. 2011;171(22):2001–2010. https://doi.org/10.1001/archinternmed.2011.507Test.; Trief P.M., Fisher L., Sandberg J., Hessler D.M., Cibula D.A., Weinstock R.S. Two for one? Effects of a couples intervention on partners of persons with Type 2 diabetes: a randomized controlled trial. Diabet Med. 2019;36(4):473–481. https://doi.org/10.1111/dme.13871Test.; Liao J., Wu X., Wang C., Xiao X., Cai Y., Wu M. et al. Couple-based collaborative management model of type 2 diabetes mellitus for community-dwelling older adults in China: protocol for a hybrid type 1 randomized controlled trial. BMC Geriatr. 2020;20(1):123. https://doi.org/10.1186/s12877-020-01528-5Test.; Gilden J.L., Hendryx M., Casia C., Singh S.P. The effectiveness of diabetes education programs for older patients and their spouses. J Am Geriatr Soc. 1989;37(11):1023–1030. https://doi.org/10.1111/j.1532-5415.1989.tb06915.xTest; Shea S., Weinstock R.S., Teresi J.A., Palmas W., Starren J., Cimino J.J. et al. A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus: 5 year results of the IDEATel study. J Am Med Inform Assoc. 2009;16(4):446–456. https://doi.org/10.1197/jamia.M3157Test.; Portz J.D., LaMendola W.F. Participation, Retention, and Utilization of a WebBased Chronic Disease Self-Management Intervention among Older Adults. Telemed J E Health. 2019;25(2):126–131. https://doi.org/10.1089/tmj.2017.0208Test.; Kirkman M.S., Briscoe V.J., Clark N., Florez H., Haas L.B., Halter J.B. et al. Diabetes in older adults: a consensus report. J Am Geriatr Soc. 2012;60(12):2342–2356. https://doi.org/10.1111/jgs.12035Test.; Ткачева О.Н., Котовская Ю.В., Рунихина Н.К., Фролова Е.В., Наумов А.В., Воробьева Н.М. и др. Клинические рекомендации «Старческая астения». Российский журнал гериатрической медицины. 2020;(1):11–46. https://doi.org/10.37586/2686-8636-1-2020-11-46Test.; Munshi M.N., Segal A.R., Suhl E., Ryan C., Sternthal A., Giusti J. et al. Assessment of barriers to improve diabetes management in older adults: a randomized controlled study. Diabetes Care. 2013;36(3):543–549. https://doi.org/10.2337/dc12-1303Test.; Матюшкина Е.А., Суплотова Л.А., Сметанина С.А. Влияние вовлеченности членов семьи в процесс достижения оптимального уровня гликемического контроля у пациентов с сахарным диабетом 2-го типа пожилого возраста. В: Сахарный диабет в XXI веке – время объединения усилий: сборник тезисов VII Всероссийского диабетологического конгресса. Москва, 24–28 февраля 2015 г. М.: УП Принт; 2015. С. 295. Режим доступа: https://www.elibrary.ru/item.asp?id=23096336Test.; Ткачева О.Н., Остроумова О.Д., Котовская Ю.В. (ред.). Основы гериатрии. М.: ГЭОТАР-Медиа; 2020. 208 с.; Munshi M.N. Cognitive Dysfunction in Older Adults With Diabetes: What a Clinician Needs to Know. Diabetes Care. 2017;40(4):461–467. https://doi.org/10.2337/dc16-1229Test.; Irazoki E., Contreras-Somoza L.M., Toribio-Guzmán J.M., Jenaro-Río C., van der Roest H., Franco-Martín M.A. Technologies for Cognitive Training and Cognitive Rehabilitation for People with Mild Cognitive Impairment and Dementia. A Systematic Review. Front Psychol. 2020;11:648. https://doi.org/10.3389/fpsyg.2020.00648Test.; Schiel R., Braun A., Müller R., Helbich C., Siefke S., Franke I. et al. A structured treatment and educational program for patients with type 2 diabetes mellitus, insulin therapy and impaired cognitive function (DikoL). Med Klin (Munich). 2004;99(6):285–292. (In German) https://doi.org/10.1007/s00063-004-1042-5Test; Rovner B.W., Casten R.J., Piersol C.V., White N., Kelley M., Leiby B.E. Improving Glycemic Control in African Americans With Diabetes and Mild Cognitive Impairment. J Am Geriatr Soc. 2020;68(5):1015–1022. https://doi.org/10.1111/jgs.16339Test.; Ткачева О.Н., Фролова Е.В., Яхно Н.Н. (ред.). Гериатрия: национальное руководство. М.: ГЭОТАР-Медиа; 2018. 608 с.; Ткачёва О.Н., Воробьёва Н.М., Котовская Ю.В., Остроумова О.Д., Черняева М.С., Силютина М.В. и др. Распространенность гериатрических синдромов у лиц в возрасте старше 65 лет: первые результаты российского эпидемиологического исследования ЭВКАЛИПТ. Российский кардиологический журнал. 2020;25(10):3985. https://doi.org/10.15829/1560-4071-2020-3985Test.; Thapa R., Twyana S.N., Paudyal G., Khanal S., van Nispen R., Tan S. et al. Prevalence and risk factors of diabetic retinopathy among an elderly population with diabetes in Nepal: the Bhaktapur Retina Study. Clin Ophthalmol. 2018;12:561–568. https://doi.org/10.2147/OPTH.S157560Test.; Chasens E.R., Enock M., DiNardo M. Reducing a barrier to diabetes education: identifying hearing loss in patients with diabetes. Diabetes Educ. 2010;36(6):956–964. https://doi.org/10.1177/0145721710383442Test.; Oh I.H., Lee J.H., Park D.C., Kim M., Chung J.H., Kim S.H., Yeo S.G. Hearing loss as a function of aging and diabetes mellitus: a cross sectional study. PLoS ONE. 2014;9(12):e116161. https://doi.org/10.1371/journal.pone.0116161Test.; Park M., Reynolds C.F. 3rd. Depression among older adults with diabetes mellitus. Clin Geriatr Med. 2015;31(1):117–137. https://doi.org/10.1016/j.cger.2014.08.022Test.; Masmoudi J., Damak R., Zouari H., Ouali U., Mechri A., Zouari N., Jaoua A. Prevalence and Impact of Anxiety and Depression on Type 2 Diabetes in Tunisian Patients over Sixty Years Old. Depress Res Treat. 2013;341782. https://doi.org/10.1155/2013/341782Test.; Borba A.K.O.T., Arruda I.K.G., Marques A.P.O., Leal M.C.C., Diniz A.D.S. Knowledge and attitude about diabetes self-care of older adults in primary health care. Cien Saude Colet. 2019;24(1):125–136. https://doi.org/10.1590/1413-81232018241.35052016Test.; Chen B., Zhang X., Xu X., Lv X., Yao L., Huang X. et al. Diabetes education improves depressive state in newly diagnosed patients with type 2 diabetes. Pak J Med Sci. 2013;29(5):1147–1152. https://doi.org/10.12669/pjms.295.3573Test.; Reynolds C.F. 3rd, Thomas S.B., Morse J.Q., Anderson S.J., Albert S., Dew M.A. et al. Early intervention to preempt major depression among older black and white adults. Psychiatr Serv. 2014;65(6):765–773. https://doi.org/10.1176/appi.ps.201300216Test.; Yang Y., Hu X., Zhang Q., Zou R. Diabetes mellitus and risk of falls in older adults: a systematic review and meta-analysis. Age Ageing. 2016;45(6):761–767. https://doi.org/10.1093/ageing/afw140Test.; Martinez L., Jugand R., Sarazin M., Blanchon M.A., Celarier T., Ojardias E. Therapeutic education in elderly over 75 years old living at home A pilot study of 48 patients. Geriatr Psychol Neuropsychiatr Vieil. 2020;18(1):43–52. (In French) https://doi.org/10.1684/pnv.2019.0841Test.; Дедов И.И., Шестакова М.В., Майоров А.Ю. (ред.). Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Вып. 10. М.; 2021. 222 с. Режим доступа: https://webmed.irkutsk.ru/doc/pdf/algosd.pdfTest.; Tamura Y., Omura T., Toyoshima K., Araki A. Nutrition Management in Older Adults with Diabetes: A Review on the Importance of Shifting Prevention Strategies from Metabolic Syndrome to Frailty. Nutrients. 2020;12(11):3367. https://doi.org/10.3390/nu12113367Test.; Ahmadzadeh Tori N., Shojaeizadeh D., Sum S., Hajian K. Effect of BASNEFbased nutrition education on nutritional behaviors among elderly people and Mini Nutritional Assessment on nutritional status in elderly with diabetes with type 2 diabetes (A clinical trial intervention). J Educ Health Promot. 2019;8:94. https://doi.org/10.4103/jehp.jehp_222_18Test.; Cinar A.B., Oktay I., Schou L. “Smile healthy to your diabetes”: health coachingbased intervention for oral health and diabetes management. Clin Oral Investig. 2014;18(7):1793–1801. https://doi.org/10.1007/s00784-013-1165-2Test.; Longo M., Bellastella G., Maiorino M.I., Meier J.J., Esposito K., Giugliano D. Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy. Front Endocrinol (Lausanne). 2019;10:45. https://doi.org/10.3389/fendo.2019.00045Test; Coumans C., Vandenberghe M., Fery P. High rate of errors in pillbox filling by cognitively healthy elderly people. Geriatr Psychol Neuropsychiatr Vieil. 2017;15(3):273–282. https://doi.org/10.1684/pnv.2017.0679Test.; Frank F., Bjerregaard F., Bengel J., Bitzer E.M., Heimbach B., Kaier K. et al. Local, collaborative, stepped and personalised care management for older people with chronic diseases (LoChro): study protocol of a randomised comparative effectiveness trial. BMC Geriatr. 2019;19(1):64. https://doi.org/10.1186/s12877-019-1088-0Test.; Markle-Reid M., Ploeg J., Fraser K.D., Fisher K.A., Akhtar-Danesh N., Bartholomew A. et al. The ACHRU-CPP versus usual care for older adults with type-2 diabetes and multiple chronic conditions and their family caregivers: study protocol for a randomized controlled trial. Trials. 2017;18(1):55. https://doi.org/10.1186/s13063-017-1795-9Test.; Dunbar S.B., Butts B., Reilly C.M., Gary R.A., Higgins M.K., Ferranti E.P. et al. A pilot test of an integrated self-care intervention for persons with heart failure and concomitant diabetes. Nurs Outlook. 2014;62(2):97–111. https://doi.org/10.1016/j.outlook.2013.09.003Test.; Williams J.W. Jr, Katon W., Lin E.H., Nöel P.H., Worchel J., Cornell J. et al. The effectiveness of depression care management on diabetes-related outcomes in older patients. Ann Intern Med. 2004;140(12):1015–1024. https://doi.org/10.7326/0003-4819-140-12-200406150-00012Test.; Du Pon E., Kleefstra N., Cleveringa F., van Dooren A., Heerdink E.R., van Dulmen S. Effects of the Proactive interdisciplinary self-management (PRISMA) program on self-reported and clinical outcomes in type 2 diabetes: a pragmatic randomized controlled trial. BMC Endocr Disord. 2019;19(1):139. https://doi.org/10.1186/s12902-019-0466-0Test.; https://www.med-sovet.pro/jour/article/view/6904Test

الإتاحة: https://doi.org/10.21518/2079-701X-2022-16-10-22-32Test
https://doi.org/10.4103/2230-8210.119647Test
https://doi.org/10.1186/s12889-020-09045-1Test
https://doi.org/10.2337/dc21-S012Test
https://doi.org/10.14341/DM9686Test
https://doi.org/10.1210/jc.2019-00198Test
https://doi.org/10.2337/dc15-0730Test
https://doi.org/10.1177/0145721715599268Test
https://doi.org/10.24411/2312-2935-2020-00007Test
https://doi.org/10.1016/S0140-6736Test(15)00116-6

المؤلفون: E. S. Maloletkina, O. Y. Gurova, I. V. Glinkina, M. V. Amosova, Zh. Zh. Shyman, I. A. Khaykina, M. F. Kalashnikova, V. V. Fadeev, Е. С. Малолеткина, О. Ю. Гурова, И. В. Глинкина, М. В. Амосова, Ж. Ж. Шыман, И. А. Хайкина, М. Ф. Калашникова, В. В. Фадеев

المصدر: Meditsinskiy sovet = Medical Council; № 10 (2022); 62-74 ; Медицинский Совет; № 10 (2022); 62-74 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: прандиальный инсулин, morbid obesity, insulin therapy, iSGLT-2, prandial insulin, морбидное ожирение, инсулинотерапия, иНГЛТ-2

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/6909/6240Test; Sluik D., Boeing H., Montonen J., Pischon T., Kaaks R., Teucher B. et al. Associations between general and abdominal adiposity and mortality in individuals with diabetes mellitus. Am J Epidemiol. 2011;174(1):22–34. https://doi.org/10.1093/aje/kwr048Test.; Weng W., Tian Y., Kimball E.S., Kong S.X., Bouchard J., Hobbs T.M. et al. Treatment patterns and clinical characteristics of patients with type 2 diabetes mellitus according to body mass index: findings from an electronic medical records database. BMJ Open Diabetes Res Care. 2017;5(1):e000382. https://doi.org/10.1136/bmjdrc-2016-000382Test.; Дедов И.И., Шестакова М.В., Аметов А.С., Анциферов М.Б., Галстян Г.Р., Майоров А.Ю. и др. Инициация и интенсификация сахароснижающей терапии у больных сахарным диабетом 2 типа: обновление консенсуса совета экспертов Российской ассоциации эндокринологов (2015 г.). Сахарный диабет. 2015;18(1):5–23. https://doi.org/10.14341/DM201515-23Test.; Riddle M.C., Barkis G., Blonde L., Boulton J.M., DiMenlio L.A., Gonder-Frederick L. et al. The Standards of Medical Care in Diabetes – 2021. Diabetes Care. 2021;44(1):226–232. https://doi.org/10.2337/dc21-in01Test.; Дедов И.И., Мельниченко Г.А., Шестакова М.В., Трошина Е.А., Мазурина Н.В., Шестакова Е.А. и др. Национальные клинические рекомендации по лечению морбидного ожирения у взрослых. 3-й пересмотр (лечение морбидного ожирения у взрослых). Ожирение и метаболизм. 2018;15(1):53–70. https://doi.org/10.14341/omet2018153-70Test.; Suzuki K., Mitsuma Y., Sato T., Anraku T., Hatta M. Comparison of сombined tofogliflozin and glargine, tofogliflozin added to insulin, and insulin dose-increase therapy in uncontrolled type 2 diabetes. J Clin Med Res. 2016;8(11):805814. https://doi.org/10.14740/jocmr2741wTest.; Wilding J.P., Woo V., Rohwedder K., Sugg J., Parikh S. Dapagliflozin 006 Study Group. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16(2):124–136. https://doi.org/10.1111/dom.12187Test; Rosenstock J., Jelaska A., Zeller C., Kim G., Broedl U.C., Woerle H.J. et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, doubleblind, placebo-controlled trial. Diabetes Obes Metab. 2015;17(10):936–948. https://doi.org/10.1111/dom.12503Test.; Sertbas M., Sertbas Y., Okuroglu N., Akyildiz A.B., Sancak S., Ozdemir A. Effıcacy and safety of dapagliflozin on diabetic patients receiving high-doses of insulin. Pak J Med Sci. 2019;35(2):399–403. https://doi.org/10.12669/pjms.35.2.21Test.; Yang Y., Chen S., Pan H., Zou Y., Wang B., Wang G. et al. Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: Systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96(21):e6944. https://doi.org/10.1097/MD.0000000000006944Test; Cho Y.K., Kim Y.J., Kang Y.M., Lee S.E., Park J.Y., Lee W.J. et al. Comparison between sodium-glucose cotransporter 2 inhibitors and pioglitazone as additions toinsulin therapy in type 2 diabetes patients: A systematic review with an indirect comparison meta-analysis. J Diabetes Investig. 2018;9(4):882–892. https://doi.org/10.1111/jdi.12787Test.; Yanai H., Adachi H., Hakoshima M., Katsuyama H. An effective insulin therapy in combination with sodium-glucose cotransporter 2 inhibitors. J Clin Med Res. 2019;11(1):76–79. https://doi.org/10.14740/jocmr3676Test.; Thomas M.C., Cherney D.Z.I. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018;61(10):2098– 2107. https://doi.org/10.1007/s00125-018-4669-0Test.; Lee P.C., Ganguly S., Goh S.Y. Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes Rev. 2018;19(12):1630–1641. https://doi.org/10.1111/obr.12755Test; Abdul-Ghani M.A., DeFronzo R.A., Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes. 2013;62(10):3324–3328. https://doi.org/10.2337/db13-0604Test.; Ferrannini E., Baldi S., Frascerra S., Astiarraga B., Heise T., Bizzotto R. et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65(5):1190–1195. https://doi.org/10.2337/db15-1356Test.; Kashiwagi A., Maegawa H. Metabolic and hemodynamic effects of sodiumdependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. J Diabetes Investig. 2017;8(4):416–427. https://doi.org/10.1111/jdi.12644Test.; Sakai S., Kaku K., Seino Y., Inagaki N., Haneda M., Sasaki T. et al. Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials. Clin Ther. 2016;38(4):843–862.e9. https://doi.org/10.1016/j.clinthera.2016.01.017Test.; Shatskov A., Rezvani G., Mansfield T. Efficacy and safety of dapagliflozin in patients with type 2 diabetes: outcome by body mass index. In: American Diabetic Association 76th Scientific Sessions 2016. New Orleans, Louisiana, USA, 1014 June 2016. Available at: https://ada.scientificposters.com/apprizr.cfm?bKCOsb7hrpJc2bVJSbe2aUU33p2%2BQ%-2FAWOznDBQz496Yir3QEmFsQzSStuD2Qk2MncZ%2FSFToTdxQ%3DTest.; Iemitsu K., Iizuka T., Takihata M., Takai M., Nakajima S., Minami N. et al. Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study. J Clin Med Res. 2016;8(5):373–378. https://doi.org/10.14740/jocmr2492wTest.; Zhang L., Feng Y., List J., Kasichayanula S., Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab. 2010;12(6):510–516. https://doi.org/10.1111/j.1463-1326.2010.01216.xTest.; Heerspink H.J., Perkins B.A., Fitchett D.H., Husain M., Cherney D.Z. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016;134(10):752–772. https://doi.org/10.1161/CIRCULATIONAHA.116.021887Test.; Thomas M.C. Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab. 2014;5(3):53–61. https://doi.org/10.1177/2042018814544153Test.; Мартынов С.А., Шамхалова М.Ш. Роль ингибиторов натрий-глюкозного котранспортера 2 в замедлении прогрессирования почечной недостаточности у пациентов с сахарным диабетом 2 типа. Эффективная фармакотерапия. 2021;17(5):16–23. Режим доступа: https://umedp.ru/articles/rol_ingibitorov_natriyglyukoznogo_kotransportera_2_v_zamedlenii_progressirovaniya_pochechnoy_nedosta.htmlTest.; Piperidou A., Sarafidis P., Boutou A., Thomopoulos C., Loutradis C., Alexandrou M.E. et al. The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019;37(7):1334–1343. https://doi.org/10.1097/HJH.0000000000002050Test; Luo Y., Lu K., Liu G., Wang J., Laurent I., Zhou X. The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clin Drug Investig. 2018;38(12):1089–1108. https://doi.org/10.1007/s40261-018-0707-4Test; Салухов В.В., Демидова Т.Ю. Эмпаглифлозин как новая стратегия управления исходами у пациентов с сахарным диабетом 2 типа и высоким кардиоваскулярным риском. Сахарный диабет. 2016;19(6):494–510. https://doi.org/10.14341/DM8216Test.; Gagnon-Auger M., du Souich P., Baillargeon J.P., Martin E., Brassard P., Ménard J. et al. Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. Diabetes Care. 2010;33(12):2502–2507. https://doi.org/10.2337/dc10-1126Test.; Morello C.M. Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus. Int J Gen Med. 2011;4:827–835. https://doi.org/10.2147/IJGM.S26889Test.; Plank J., Bodenlenz M., Sinner F., Magnes C., Görzer E., Regittnig W. et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28(5):1107–1112. https://doi.org/10.2337/diacare.28.5.1107Test.; Becker R.H., Frick A.D. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet. 2008;47(1):7–20. https://doi.org/10.2165/00003088-200847010-00002Test.; Lindholm A., Jacobsen L.V. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet. 2001;40(9):641–659. https://doi.org/10.2165/00003088-200140090-00002Test.; Gin H., Hanaire-Broutin H. Reproducibility and variability in the action of injected insulin. Diabetes Metab. 2005;31(1):7–13. https://doi.org/10.1016/s1262-3636Test(07)70160-x.; Barnett A.H. How well do rapid-acting insulins work in obese individuals?. Diabetes Obes Metab. 2006;8(4):388–395. https://doi.org/10.1111/j.1463-1326.2005.00525.xTest.; Frid A.H., Kreugel G., Grassi G., Halimi S., Hicks D., Hirsch L.J. et al. New Insulin Delivery Recommendations. Mayo Clin Proc. 2016;91(9):1231–1255. https://doi.org/10.1016/j.mayocp.2016.06.010Test.; Майоров А.Ю., Мельникова О.Г., Котешкова О.М., Мисникова И.В., Черникова Н.А. Техника инъекции и инфузии при лечении сахарного диабета. М.; 2018. 61 с. Режим доступа: https://rae-org.ru/system/files/documents/pdf/mr102.pdfTest.; Saryusz-Wolska M., Szymańska-Garbacz E., Pawłowski M., Loba J., Czupryniak L. Splitting high dose of insulin and injecting it in two sites improves blood glucose control. Diabetologia. 2011;54(1 Suppl.):52. https://doi.org/10.1007/s00125-011-2276-4Test.; https://www.med-sovet.pro/jour/article/view/6909Test

الإتاحة: https://doi.org/10.21518/2079-701X-2022-16-10-62-74Test
https://doi.org/10.1093/aje/kwr048Test
https://doi.org/10.1136/bmjdrc-2016-000382Test
https://doi.org/10.14341/DM201515-23Test
https://doi.org/10.2337/dc21-in01Test
https://doi.org/10.14341/omet2018153-70Test
https://doi.org/10.14740/jocmr2741wTest
https://doi.org/10.1111/dom.12187Test
https://doi.org/10.1111/dom.12503Test
https://doi.org/10.12669/pjms.35.2.21Test